You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

neoadjuvant

Showing 51 - 75 of 5,298
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neoadjuvant Immunotherapy Trial in Tianjin (tislelizumab+disitamab-vedotin)

Recruiting
  • Neoadjuvant Immunotherapy
  • Tianjin, China
    The Second Hospital of Tianjin Medical University
Apr 20, 2023

Nasopharyngeal Carcinoma Trial in Hangzhou (Toripalimab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Apr 2, 2023

Rectal Cancer Trial (CapeOX + cetuximab, CapeOX + bevacizumab, radiotherapy)

Not yet recruiting
  • Rectal Cancer
  • CapeOX + cetuximab
  • +2 more
  • (no location specified)
Sep 12, 2023

Colon Cancer, Immunotherapy Trial in Chongqing (Terelizumab, CapeOx)

Not yet recruiting
  • Colon Cancer
  • Immunotherapy
  • Chongqing, China
    Daping hospital
Apr 16, 2023

Osteosarcoma Trial (Surufatinib plus chemo, Chemotherapy)

Not yet recruiting
  • Osteosarcoma
  • (no location specified)
Jun 29, 2023

Anemia Trial in Philadelphia (Venofer)

Recruiting
  • Anemia
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Mar 24, 2023

Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue Trial in Warsaw (Pembrolizumab, Eftilagimod alpha)

Recruiting
  • Neoadjuvant
  • +3 more
  • Pembrolizumab, Eftilagimod alpha
  • Warsaw, Poland
    Maria Sklodowska-Curie National Research Institute of Oncology
Nov 7, 2023

Breast Cancer, Chemo Effect Trial (Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel, Epirubicin, Cyclophosphamide,

Not yet recruiting
  • Breast Cancer
  • Chemotherapy Effect
  • Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel
  • Epirubicin, Cyclophosphamide, Docetaxel
  • (no location specified)
Jun 21, 2023

Esophageal Cancer Trial in Wuhan

Recruiting
  • Esophageal Cancer
    • Wuhan, Hubei, China
      Renmin hosptial of Wuhan University
    Jun 7, 2023

    Rectal Cancer in a Tertiary Asian Institute

    Completed
    • Rectal Cancer
    • Oncology
    • neoadjuvant long course chemoradiotherapy
    • (no location specified)
    Oct 31, 2022

    Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced

    Completed
    • Oral Cancer
    • PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital
    Nov 20, 2023

    Locally Advanced Hypopharyngeal Carcinoma Trial in Shanghai (drug, procedure, radiation)

    Not yet recruiting
    • Locally Advanced Hypopharyngeal Carcinoma
    • three cycles (toripalimab + cetuximab + platinum)
    • +2 more
    • Shanghai, Shanghai, China
      Eye & ENT Hospital of Fudan University
    Nov 22, 2023

    Rectal Cancer Trial (Trifluridine/Tipiracil, intensity-modulated radiotherapy)

    Not yet recruiting
    • Rectal Cancer
    • (no location specified)
    Jul 27, 2023

    Neoadjuvant Chemo, PD-1 Antibody, Radiotherapy Trial (neoadjuvant chemo combined with PD-1 antibody + radical radiotherapy)

    Not yet recruiting
    • Neoadjuvant Chemotherapy
    • +3 more
    • neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
    • (no location specified)
    Sep 21, 2022

    Breast Cancer, Breast Tumors, Breast Cancer Female Trial in Istanbul (Axillary sentinal lymph node biopsy)

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Axillary sentinal lymph node biopsy
    • İstanbul, Bagcilar, Turkey
    • +1 more
    Oct 22, 2023

    Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • +2 more
    • Beijing, Beijing, China
      Beijing Tongren Hospital
    Oct 26, 2023

    Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced

    Recruiting
    • Gastric Cancer
    • Gastric Adenocarcinoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 4, 2023

    Breast Cancer Trial (Arm I (No PMRT), Arm II (PMRT))

    Not yet recruiting
    • Breast Cancer
    • Arm I (No PMRT)
    • Arm II (PMRT)
    • (no location specified)
    Aug 8, 2023

    Nasopharyngeal Carcinoma Trial in Shanghai (Camrelizumab, Nimotuzumab, neoadjuvant chemo and CCRT)

    Recruiting
    • Nasopharyngeal Carcinoma
    • Shanghai, Shanghai, China
      Fudan Universtiy Shanghai Cancer Centre
    Mar 6, 2023

    Merkel Cell Carcinoma Trial in Wollstonecraft (Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination)

    Not yet recruiting
    • Merkel Cell Carcinoma
    • Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
    • Wollstonecraft, New South Wales, Australia
      Melanoma Institute Australia
    Nov 21, 2023

    Soft Tissue Sarcoma, Adult Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma Trial in Lyon (radiation, other, procedure)

    Not yet recruiting
    • Soft Tissue Sarcoma
    • +2 more
    • Neoadjuvant RT
    • +3 more
    • Lyon, Rhône, France
      Centre Léon Bérard
    Jan 12, 2023

    Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

    Not yet recruiting
    • Urothelial Carcinoma Bladder
    • Androgen Receptor Positive
    • Providence, Rhode Island
      Lifespan Cancer Institute
    May 1, 2023

    Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

    Not yet recruiting
    • Colorectal Cancer
    • Serplulimab + FOLFOXIRI
    • Radiation therapy
    • (no location specified)
    Oct 24, 2023

    Locally Advanced Cervical Cancer Trial in Xi'an (Zimberelimab, Albumin-bound Paclitaxel, Cisplatin)

    Recruiting
    • Locally Advanced Cervical Cancer
    • Xi'an, Shaanxi, China
      Hongxi Zhao
    Sep 20, 2023

    NSCLC, Stage II-IIIA, Immunotherapy Trial in Shanghai (Serplulimab and Chemotherapy)

    Recruiting
    • Non-small Cell Lung Cancer
    • +3 more
    • Serplulimab and Chemotherapy
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 27, 2023